The neurokinin (NK) receptor family has been proposed as targets for neural-related diseases. The experimental studies indicate that this family of receptors might also be targets for malignancies, both solid and hematological tumors. However, an understanding of the biology of other rmolecules with sequence similarity to NK receptors is required. Of significance is the HGFIN gene that shares structural homology with NK1. Through this homology, the HGFIN interacts with the high affinity ligand of NK1, substance P. This report discusses potential applications for targets against NK receptors, and the role of HGFIN in drug designs. This review is relevant for central and peripheral nervous system drug development, and also cancer drugs for breast and neuroblastoma. The potential for leukemia drugs and Patents are also discussed.
BONE MARROW BIOLOGY
In adults, the bone marrow is the major site of hematopoiesis, which is the development of immune and other blood cells from a relatively small number of self-renewing hematopoietic stem cell [1] [2] [3] . The biology of bone marrow could be considered as an active process beginning from the hematopoietic stem cells. Through this process, the bone marrow is able to replenish the immune system throughout life, therefore making the adult bone marrow as the major organ of the emerging immune system [4] . A hematopoietic stem cell undergoes self-renewal, and when it divides, it follows a pattern of asymmetry to commit into a common myeloid or lymphoid progenitor [1] [2] [3] . Common myeloid progenitors generate cell lineages that develop into dendritic cells, erythrocytes, megakaryocytes and granulocytes [5] . Common lymphoid progenitors mature towards B-, T-, natural killer and dendritic cells [6, 7] . T-cell development involves a complex process beginning from common lymphoid progenitor to mature pro-T-cells, followed by maturation and selection mainly in the thymus [8] [9] [10] .
Hematopoiesis is regulated by soluble factors, extracellular matrix proteins, and also through cell-cell interactions that involve different families of adhesion molecules [11] [12] [13] [14] [15] . Examples of hematopoietic relevant soluble factors are cytokines, neurotrophic factors, neuropeptides and neurotransmitters [16] [17] [18] [19] [20] [21] [22] [23] . Bone marrow stromal cells support hematopoietic activity, mainly due to the expression of genes for hematopoietic growth factors and extracellular matrix proteins [11] . The stromal cells, through their expression of various molecules form cellular interactions with the cognate receptors on hematopoietic stem cells, thereby retain the latter within bone marrow [11, 24, 25] . Stromal cells, when established in vitro, comprise fibroblasts *Address correspondence to this author at the UMDNJ-New Jersey Medical School, MSB, 185 South Orange Ave, Newark, NJ 07103, USA; Tel: (973) 972 0625; Fax: (973) 972 8854; E-mail: rameshwa@umdnj.edu (major subset) and minor subsets: endothelial cells, macrophages, reticular cells and adipocytes [13] . However, the stromal cells, which are fibroblastoid could be selected as purified cultures for experimental analyses. The stromal cells are the major support for hemato-poiesis, instructing lineage commitment and differentiation at various regions within the hierarchy of cell lineages [13] . Stromal cells are involved in the protection of hematopoietic stem cells from damaging insults caused by chemical exposures, viral infection and anoxia [26] [27] [28] . Stroma could respond to various stimuli and produce factors that act through autocrine and/or paracrine mechanisms to regulate hematopoiesis [13] .
TACHYKININS AND NEUROKININ (NK) RECEP-TORS
The Tac1 gene (also referred as preprotachykinin-I, or preprotachykinin-A) is a single copy gene with 7 exons, encodes several evolutionary conserved peptides that belong to the tachykinin family [29] [30] [31] [32] [33] [34] [35] . The tachykinins share a common sequence in their -COOH termini [29] . The Tac1 transcript is alternatively spliced into one of four transcripts: α-, β-, γ-or ∆-forms [31] [32] [33] [34] [35] . The major peptides of Tac1 are substance P and neurokinin A. Substance P is encoded by Exon 3, which is present in each of the four types of transcripts [30] . Neurokinin-A is encoded by Exon 6, which is present on two of the four possible transcripts, β-and γ-forms [34] .
Substance P is the most studied peptide among the tachykinins [36, 37] . It is an undecapeptide that is widely distributed in the central and peripheral nervous systems [29] . Substance P is released in the periphery as a neurotransmitter, and is also produced from non-neural cells, which include immune and bone marrow stromal cells [35, 38, 39] . The expression of Tac1 appears to be tissuespecific. For example, Tac1 is constitutively expressed in neurons and its peptides are stored in synaptic vesicles [40] [41] [42] [43] , while its induction in bone marrow stromal cells requires cell stimulation [38] . Tac1 could be induced by different stimuli including cytokines, neurotrophic factors, lippopolysaccharide, glucocorticoids, neuropeptides and neuronal depolarization [38] [39] [40] [41] [42] [43] [44] . Substance P has been reported to regulate its production [42] . Whether this selfinduction of substance P is direct or indirectly mediated through other soluble factors remains to be determined. Nonneural functions of the Tac1 peptides include immune and hematopoietic modulation [38] . Substance P has a role in Tcell development after the T-cell progenitors have migrated from the bone marrow to the thymus [45] . Tac1 has been linked to several clinical disorders (described below). Recently, a third tachykinin gene (PPT-C) has been identified and its associated peptide, hemokinin 1, has been grouped under the `umbrella' of tachykinins [46] . PPT-C expression is expressed in hematopoietic cells with hematopoietic effects by hemokinin 1 [46] .
The tachykinins bind with different affinities to three mammalian G protein-coupled, 7-transmembrane receptors: NK1, NK2 and NK3 [36] . Substance P and Neurokinin-A exhibit binding preferences for NK1 and NK2 respectively [36] . In addition to the NK receptors, the tachykinins can also interact with other molecules that share homology with the NK family [47] . Substance P has been reported to interact with fibronectin and a single transmembrane spanning protein, HGFIN [47, 48] .
The original thoughts were that NK1 and NK2 are mostly expressed in peripheral tissues, and NK3 is expressed mostly in the brain [29] . However, more recent studies have shown wide expression of NK1 in whole brain of mammals and wide distribution in various peripheral tissues [49] [50] [51] . Similarly, more recent reports show NK3 widely expressed in a variety of peripher tissues, including the kidney, lung, placenta, and skeletal muscle [49] [50] [51] . In the periphery, NK1 and NK2 expressions are found on many tissues including mammary epithelial, bone marrow cells (hematopoietic and mesenchymal type) [52] . In most healthy non-neural cells, NK1 expression requires cell stimulation, whereas NK2 has been found to be constitutively expressed [53] . When NK1 is expressed in healthy cells, NK2 is down regulated [53] . This type of yin-yang expression between NK1 and NK2 appears to be regulated at the molecular and intracellular levels using second messengers as mediators. The method by which one receptor affects the other is referred as receptor crosstalk [53] .
NK1 is capable of undergoing reversible desensitization with prolonged exposures to high concentrations of its ligand [54, 55] . At optimal stimulation, NK1 inactivation is accompanied by its internalization [54] . NK receptors and their ligands are central to the cellular and humoral compartment within a complex network involved in bone marrow biology [56] [57] [58] [59] . NK receptors are expressed on cells within hematopoietic lineages [39, 45, 46, 53, 60] , indicating that the tachykinins could directly regulate hematopoiesis, in addition to indirect effects through stromal cells [38] .
NK RECEPTORS AND BONE MARROW FUNC-TIONS
Cytokines are considered as prototypic hematopoietic regulators [21] . Neuropeptides, neurotransmitters, neurotrophic factors, neurohormones and other hormones regulate hematopoiesis [61] [62] [63] [64] . The tachykinins are under the category of neurotransmitters/ neuropeptides. Members of the tachykinin family interact with the three gene products of three cloned NK receptors. However, NK1 and NK2 are identified on bone marrow cells [38] .
The biological functions exerted by NK1 and NK2 on normal cells occur by these receptors acting in opposing manner. For example, in hematopoiesis while NK1 mediates stimulatory effect, NK2 exerts suppressive functions [38] . However, these regulated functions are lost in malignant cells, that is, cells from solid tumors such as breast cancer, and in hematological malignancies [65] .
The Tac1 gene has been found to be required for the entry of breast cancer cells into the bone marrow, and its expression has a critical role to allowing the breast cancer cells to enter the bone marrow at an early period of cancer, long before cancer development [65] . In other studies, substance P, the major Tac1 peptide, is highly produced in leukemia cells and its production could lead to bone marrow fibrosis [66] . If substance P levels are high, increased proliferation of the hematopoietic progenitors is a risk for genetic and epigenetic mutations, which could cause leukemia and myeloproliferative disorders.
NK RECEPTORS AS POTENTIAL DRUG TARGETS, PATENTS: BENEFIT AND CONFOUNDS
Fibronectin shares structural similarity with NK1, suggesting possible interactions between fibronectin and the high affinity ligand for NK1, substance P [48] . Insights into this similarity were derived from substance P binding to fibronectin [48] . The interaction between substance P and fibronectin is significant because in normal bone marrow, fibronectin is a component of extracellular matrix proteins that surrounds the stroma [12] . Since both NK1 and fibronectin are relevant to hematopoiesis, then one can argue that both NK1 and fibronectin could be competing for the substance P [12, 53] . While similarity between fibronectin and NK1 could be advantageous to hematopoiesis, this could also cause pathology of bone marrow.
Substance P is a small peptide that is easily susceptible to degradation by endopeptidases [66] . In a healthy bone marrow where there is homeostasis, fibronectin could protect substance P from endogenous endopeptidases [4, 66] . Increased levels of substance P have been reported in the circulation of patients with myelofibrosis, and have also been show to be produced by leukemic cells [52] . Substance P mediates angiogenesis, enhances cell proliferation, and also promotes fibrosis [35] . These qualities underlay several properties linked to malignancy. In this regard, antagonists to the substance P receptor could be indicated for treatment of patients with myelofibrosis. The confounds for therapeutic application of NK1 receptor antagonists as therapy for the above is that the receptor would be blocked but the ligand would be still available to interact with fibronectin, and also the molecules that share similarity with NK1. Thus, one might consider targeted therapies for both NK1 and NK2. In the absence of signaling by these receptors, it is likely that cytokine levels would drop and reversed NK receptor expression to a balance. Substance P has been reported to facilitate viral infections including HIV-1 [67] [68] [69] . Substance P/NK1-NK3 are also implicated in malignancies, hematological and solid tumors [52, 65, 70, 71] . The latter includes neuroblastoma and breast cancer [49, 70, 71] . Dysregulated production of substance P and its receptors are linked to Parkinson's, Alzheimer's, other nervous system inflammation, depression, traumatic brain injury, predisposition to anxiety, ischemia of the brain and epileptic seizures [72] [73] [74] [75] [76] [77] [78] . While NK receptor antagonists could be indicated for all of the above disorders, there is potential for other areas of dysfunctions. The association between NK receptors and bone marrow functions suggest that the associated antagonists might be indicated for novel and/or improved treatments for disorders that disrupt the bone marrow, e.g. anemia, myeloma, myelo-and lymho-proliferative disorders.
An interesting report pertains to similarity between viral proteins and members of the tachykinins. Virokinin, released from viral-infected cells shares similarity with tachykinins, based on immunoreactive methods, and it also interacts with NK1 [79] . Thus, during viral infection, perhaps virokinin could be a marker for indication to treat with NK antagonists.
A wide body of literature shows compelling evidence that psychological stress leads to immune suppression. Since the hematopoietic system is the site where the immune cells are generated, then these studies could open avenues for targeted research with in vivo models. Santarelli et al. reported on a role for NK1 receptor in anxiety and stressrelated responses [76] . The authors used robust analyses with NK1 knockout mice, and pharmacological agents. The preclinical trials in animal models support therapeutic benefits with NK1 antagonists in brain-associated disorders [80] . Ongoing and future clinical trials will determine whether NK1 could be used in central disorders such as anxiety, or as a modulator of hematopoiesis, or bone marrow-resident tumor cells [65] .
There are several antagonists for NK receptors with some exerting effects, specific for a particular subtype. A recent Patent [81] was issued for a broad-based disease, pain, irritable bowel syndrome, anxiety and pancreatitis. This compound is a substituted 1,4-di-piperidin-4-yl-piperazine derivative with NK1 antagonistic activity. For other disorders, Alzheimer's disease, neuropathy, movement disorders, drug addiction and overlapping functions of another compound [81], a 2-aminoquinoline carboxamide compound with NK3 antagonistic activity [82] . Interestingly, other NK1 antagonists have been developed to improve injection site tolerance, although the drug effects are similar to other similar antagonists [83] . When the indications are for receptor-specific antagonists are examined, it is clear that both NK1 and NK3 have similar functions. Thus, it might be prudent to carefully examine a compound that can block each of the three NK receptors. Janseens et al. [84] have a patent issued that is a substituted 1-piperdin-4-yl-4-pyrolidin-3-yl-piperazine derivative with anti-inflammatory activity [84] . The question is whether these compounds with combined antagonistic activities can be used for neural disorders such as anxiety and depression or for inflammatory purposes alone. These are questions that require further research studies in animal models.
HGFIN: RELATIONSHIP TO THE TACHYKININS AND BREAST CANCER
Another molecule has been identified that interact with the major mammalian tachykinin, substance P, designated HGFIN by some research group, and nmb by others [47, 85] . The designation, HGFIN is related to sequence homology with NK1, hence the name Hematopoietic Growth Factor Inducible Neurokinin-1 type. HGFIN is a single transmembrane protein [47] . Computational analyses, including sequence alignment, and proteomic studies indicate that HGFIN can bind to substance P [47] . Both HGFIN and Tac1 are both located on chromosome 7. HGFIN has been shown to be expressed in differentiated BM cells, which are immune cells found in the peripheral circulation [47] . HGFIN was undetectable in BM progenitors, which represent a population of highly proliferating cells [47] . Since differentiated cells are in G0/G1 phase and progenitors are in G2/S phase, the expression of HGFIN suggests that it might be linked to cell cycle checkpoints.
Genes similar to HGFIN have been linked to malignancies. Nmb confers low metastatic potential in melanoma cells [85] . Its homolog in mice, which is a longer form of the murine-related gene, osteoactivin, showed bone invasion and confers an aggressive form of tumor in mice [86] . Osteoactivin is expressed in several cancers, including breast cancer [86] . Computer alignment indicates that the human HGFIN is a truncated form of murine osteoactivin. The primary structure of HGFIN protein with its homologous proteins from rat and mouse is shown in Fig. 1 . The binding site for substance P is shown in the underlined section [47] . The residues that interact with NK1 are located within this underlined region, which is similar to regions within the polycystic kidney disease gene [47] .
At the molecular level, HGFIN is regulated by p53 with multiple binding sites in its 5′ flanking region [84] . It is not unusual for a gene that has been designated tumor suppressor to also exert oncogenic property [87] . The expression of HGFIN in non-cycling cells, combined with its regulation by p53 suggests tumor suppressor functions. On the other hand, HGFIN has been linked to tumorigenesis, not only in breast cancer, but also in melanoma [85] , suggesting oncogenic properties of HGFIN.
Interaction between HGFIN and the major Tac1 peptide, substance P, could partly explain why HGFIN is considered a tumor suppressor gene. The short cytoplasmic tail of HGFIN might have minimal intracellular signaling abilities [47] . Therefore if HGFIN acts as a decoy by binding substance P, this ligand (proposed as oncogenic) would be unavailable to mediate intracellular signaling through the truncated NK1, which is present on breast cancer cells [88] . Of note is that HGFIN is located closely to PDGF, a gene that some considered as an oncogene [89] . General sequence homology searches of the human genomic data base for potential regions of instability were searched using microsatellites as indicators. The outcome showed microsatellites flanking the chromosome region where HGFIN and PDGF are located. Since microsatellites could lead to genomic instability, then it is possible that dysregulation of HGFIN might be linked to tumorigenesis. These are ongoing studies in the laboratory with paired samples of breast cancer cells from patients diagnosed with different stages of breast cancer.
CURRENT & FUTURE DEVELOPMENTS
Before discussing the link between HGFIN and NK1 with regards to drug targeting, it is essential to provide a background on NK1 in both breast cancer and neuroblastoma. The latter has been shown to proliferate through autocrine expression of the Tac1 gene and stimulation of both the NK1 and NK2 receptors. Interestingly, when signaling of NK1 was blocked, the neuroblastoma showed a differentiation phenotype [90] . In normal cells, HGFIN acts as a tumor suppressor type molecule [87] . However, this gene also exhibits oncogenic property [86] . Thus therapy in brain would require combined treatment with targets against HGFIN and NK receptors.
Future research studies are needed to determine how HGFIN is affected during target of NK receptors. Another question is whether HGFIN, which binds to substance P might be responsible for the confounding outcome in the treatments with NK receptor antagonists. Since NK receptors appear not to have shown any significant effects from placebo groups of patients with neural disorders, it might be prudent to focus on the HGFIN gene as potential drug targets [91] . Also, the past failures might be due to untoward or inefficiencies of the older formulae of NK receptor antagonists. The recent issue of patents [81] [82] [83] [84] , when studied need to consider how HGFIN could mask their effects in future investigational studies. Fig. (1) . Amino acid alignment of HGFIN from human with homologous proteins in rat and mouse. Underlined residues show the sequence that binds substance P.
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